Solid composition

By adding tranexamic acid to the combination of nicotinamide and ascorbic acid, the problem of discoloration of nicotinamide and ascorbic acid in the aqueous solution is solved, and the white state of the solid composition is maintained, and it is suitable for the production of various dosage forms.

CN118891044APending Publication Date: 2024-11-01DAIICHI SANKYO HEALTHCARE
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202380027651.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-14
Filing Date
2023-03-13
Publication Date
2024-11-01

AI Technical Summary

Technical Problem

When nicotinamide and ascorbic acid are mixed in a solid state, the aqueous solution is prone to change color to yellow, making it difficult to maintain a white state, especially when exposed to water or alcohol during the manufacturing process.

Method used

By adding tranexamic acid, the combination of nicotinamide and ascorbic acid is prevented from discoloring, thereby forming a solid composition that is not prone to yellowing.

Benefits of technology

Through the combination of tranexamic acid, the yellowing of nicotinamide and ascorbic acid is successfully prevented, and the composition is kept white, and it is suitable for various dosage forms such as tablets and granules.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005042601100000211
    Figure BDA0005042601100000211
  • Figure BDA0005042601100000221
    Figure BDA0005042601100000221
  • Figure BDA0005042601100000231
    Figure BDA0005042601100000231
Patent Text Reader

Abstract

The present invention provides a solid composition containing nicotinamide, ascorbic acid, and tranexamic acid.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention generally relates to solid compositions containing niacinamide, ascorbic acid and tranexamic acid. Background Art

[0002] Niacinamide, one of the B vitamins, and ascorbic acid, vitamin C, are ingredients commonly added to supplements, cosmetics, etc. It is known that when these two are dissolved in combination, the aqueous solution becomes yellow and yellow needle-shaped crystals precipitate when cooled (Non-Patent Document 1).

[0003] Nicotinamide and ascorbic acid appear white when mixed in a solid state, but change color to yellow when granulated with water, alcohol, or a mixture thereof. Therefore, in the case where nicotinamide and ascorbic acid are contained in a solid composition that has been subjected to a process of exposing the components to water, alcohol, or a mixture thereof, such as wet granulation in the manufacturing process, it has been difficult to provide the solid composition in a white state.

[0004] Prior art literature

[0005] Non-patent literature

[0006] Non-patent document 1: Okazaki Yukatsu et al., Analytical Chemistry 17(10), 1228-1233, 1968 Summary of the invention

[0007] Problems to be solved by the invention

[0008] The problem to be solved by the present invention is to provide a solid composition containing niacinamide and ascorbic acid which is less likely to turn yellow.

[0009] Means for solving problems

[0010] The present inventors surprisingly found that yellowing is prevented by the presence of tranexamic acid even under conditions where a combination of nicotinamide and ascorbic acid causes discoloration, thereby completing the present invention.

[0011] That is, the present application includes the following inventions. [1]

[0013] A solid composition comprising niacinamide, ascorbic acid and tranexamic acid. [2]

[0015] The solid composition according to [1], further comprising calcium pantothenate. [3]

[0017] The solid composition according to [1] or [2], further comprising pyridoxine hydrochloride. [4]

[0019] The solid composition according to any one of [1] to [3], comprising 6 mg to 400 mg of niacinamide, 10 mg to 3000 mg of ascorbic acid, and 50 mg to 3000 mg of tranexamic acid per day of the composition. [5]

[0021] The solid composition according to any one of [1] to [3], wherein the content of niacinamide is 1% to 5% by mass, the content of ascorbic acid is 5% to 30% by mass, and the content of tranexamic acid is 20% to 60% by mass, based on the composition. [6]

[0023] The solid composition according to any one of [1] to [5], wherein the solid composition is in the form of a tablet. [7]

[0025] The solid composition according to any one of [1] to [6], wherein the tablet is a bare tablet, a plain tablet, a sugar-coated tablet, an orally disintegrating tablet, a film-coated tablet or a chewable tablet. [8]

[0027] The solid composition according to any one of [1] to [7], further comprising one or more components selected from the group consisting of microcrystalline cellulose, mannitol and corn starch. [9]

[0029] The solid composition according to any one of [1] to [8], wherein the combination of niacinamide, ascorbic acid and tranexamic acid exhibits white color.

[0030] Effects of the Invention

[0031] According to the present invention, yellowing of a combination of nicotinamide and ascorbic acid can be prevented simply by adding tranexamic acid. DETAILED DESCRIPTION

[0032] Hereinafter, an embodiment of the present invention (hereinafter referred to as “the present embodiment”) will be described, but the scope of the present invention should not be construed as being limited to the following embodiment.

[0033] (Composition)

[0034] In a first embodiment, a solid composition containing nicotinamide, ascorbic acid and tranexamic acid is provided.

[0035] Niacinamide contained in the composition is originally a white solid, and is also called nicotinamide or vitamin B3. Niacinamide is contained in cosmetics and the like in anticipation of its whitening effect, but the use of the composition of the present invention is not particularly limited.

[0036] The amount of niacinamide added is appropriately adjusted according to the purpose of the niacinamide in the composition, the symptoms, age, weight, sex, etc. of the subject to be administered. For example, in the case of niacinamide for the purpose of whitening, the amount of niacinamide administered to adults per day can be adjusted within the range of 1 mg to 500 mg, preferably 6 mg to 400 mg, and more preferably 10 mg to 200 mg. In the present invention, "adults" refer to men and women over 15 years old. However, the composition of the present invention is not limited to a composition for adults to take, and can also be a composition for children under 15 years old. When taken by children, it can be reduced to 1 / 2, 2 / 3, etc. of the amount taken by adults per day according to each age group.

[0037] The above dosage is an example. Examples of the amount of niacinamide relative to a composition of about 1000 mg to about 4000 mg, preferably about 1500 mg to about 1800 mg, administered per day include about 10 mg to about 70 mg, about 15 mg to about 65 mg, about 20 mg to about 60 mg, about 25 mg to about 55 mg, about 30 mg to about 50 mg, and about 35 mg to about 45 mg.

[0038] The weight and dosage of the above composition are dosages per day (1 day dose), but the amount can also be divided into multiple times per day, for example, 2 or 3 times, preferably 2 times, and administered to the subject. The same applies to ingredients other than nicotinamide. In addition, since each dosage is a total amount, the content of each ingredient contained in the composition can be changed according to the single dosage, the dosage form of the composition, etc.

[0039] In a specific embodiment, the composition is a tablet, and the dosage is the amount of the ingredients contained in 4, 6 or 8 tablets, preferably the amount of the ingredients in 4 tablets. In this embodiment, the dosage for adults (over 15 years old) is 2 times, and the dosage for 1 time is 2 tablets, 3 tablets or 4 tablets, preferably 2 tablets.

[0040] The ascorbic acid incorporated in the composition is originally a white or light yellow solid. The ascorbic acid used in this specification is the L-form, which is also called vitamin C. In addition to being incorporated into foods and the like in anticipation of the antioxidant effect of ascorbic acid, it is also incorporated into cosmetics and the like for the purpose of preventing the symptoms of spots (Japanese: シミ) or liver spots because it inhibits the production of melanin.

[0041] Ascorbic acid may be in the form of a salt or a derivative. Examples of the salt of ascorbic acid include inorganic acid salts such as hydrochlorides, nitrates, and sulfates, alkali metal salts such as sodium salts, potassium salts, calcium salts, and magnesium salts, and alkaline earth metal salts. Examples of ascorbic acid, its derivatives, or salts thereof include ascorbic acid; ascorbic acid salts such as sodium ascorbate, magnesium ascorbate, potassium ascorbate, and calcium ascorbate; ascorbic acid monoalkyl esters or monoalkenyl esters such as ascorbic acid monostearate, ascorbic acid monopalmitate, and ascorbic acid monooleate; ascorbic acid dialkyl esters or dienyl esters such as ascorbic distearate, ascorbic dipalmitate, and ascorbic dioleate; ascorbic acid tristearate, ascorbic acid monostearate, and ascorbic acid monooleate; Ascorbic acid trialkyl esters or trienyl esters such as ascorbic acid tripalmitate and ascorbyl trioleate; ascorbic acid sulfates (salts) such as ascorbyl sulfate, sodium ascorbyl sulfate, potassium ascorbyl sulfate, magnesium ascorbyl sulfate, and calcium ascorbyl sulfate; ascorbic acid phosphates (salts) such as ascorbyl phosphate, sodium ascorbyl phosphate, potassium ascorbyl phosphate, magnesium ascorbyl phosphate, and calcium ascorbyl phosphate; ascorbic acid glycosides such as ascorbyl glycosides, etc.

[0042] The amount of ascorbic acid added is appropriately adjusted depending on the use of the ascorbic acid in the composition, the symptoms, age, weight, sex, etc. of the subject to be administered. For example, when ascorbic acid is added for the purpose of preventing the symptoms of spots or liver spots, the amount of ascorbic acid administered to an adult per day can be adjusted within the range of 1 mg to 5000 mg, preferably 10 mg to 3000 mg, and more preferably 20 mg to 2000 mg.

[0043] The above dosage is an example. Examples of the amount of ascorbic acid relative to a composition of about 1000 mg to about 4000 mg, preferably about 1500 mg to about 1800 mg, administered per day include about 50 mg to about 2000 mg, about 75 mg to about 1750 mg, about 100 mg to about 1500 mg, about 200 mg to about 1000 mg, and about 250 mg to about 350 mg.

[0044] Tranexamic acid (trans-4-aminomethylcyclohexanecarboxylic acid) contained in the composition is originally a white solid. In addition to being contained in pharmaceuticals and the like in anti-inflammatory effects thereof, tranexamic acid is also contained in cosmetics and the like for the purpose of preventing symptoms of spots or liver spots.

[0045] Tranexamic acid can be in the form of a salt. As long as there is no special description, the salt of tranexamic acid is also included in the tranexamic acid when used in this specification. As the salt of tranexamic acid, inorganic acid salts such as hydrochloride, nitrate, sulfate, organic acid salts such as mesylate, sodium salt, potassium salt, calcium salt, magnesium salt, alkali metal salts, alkaline earth metal salts etc. can be enumerated.

[0046] The amount of tranexamic acid can be appropriately adjusted according to the amount of nicotinamide and ascorbic acid, the degree of the desired discoloration inhibition effect, and when it is added in anticipation of other medicinal effects while preventing yellowing, it can be appropriately adjusted according to the use of the tranexamic acid in the composition, the symptoms, age, weight, sex, etc. of the object to be administered. For example, in the case of preventing the symptoms of spots or liver spots, the amount of tranexamic acid administered to adults per day can be adjusted within the range of 5 mg to 5000 mg, preferably 50 mg to 3000 mg, and more preferably 100 mg to 2000 mg.

[0047] The above dosage is an example. Examples of the amount of tranexamic acid relative to a composition with a weight of about 1000 mg to about 4000 mg, preferably about 1500 mg to about 1800 mg administered per day include about 500 mg to about 1000 mg, about 550 mg to about 950 mg, about 600 mg to about 900 mg, about 650 mg to about 850 mg, about 700 mg to about 800 mg, etc.

[0048] The composition of the present invention can be administered orally or parenterally. Examples of oral compositions (oral preparations) include tablets, granules, pills, powders, and the like. Parenterally administered compositions (parenterally administered preparations) are not particularly limited as long as they are solid dosage forms.

[0049] In the range that does not impair the effect of tranexamic acid, the composition can further arbitrarily be matched with other ingredients, for example, known carriers, additives and other formulation additives. As these formulation additives, for example, excipients, binders, disintegrants, disintegration aids, lubricants, stabilizers, surfactants, antioxidants, buffers, pH adjusters, dispersants, solubilizers, flow agents, glossing agents, flavoring agents, sweeteners, cooling agents, colorants, deodorants, fragrances, adsorbents, sugar coating agents, coating agents, suspending agents, antistatic agents, plasticizers and aromatics can be exemplified without limitation.

[0050] The excipient is not limited as long as the effect of tranexamic acid is not impaired, and examples thereof include microcrystalline cellulose, lactose hydrate, refined white sugar, glucose, powdered sugar, fructose, maltose, reduced maltose syrup, powdered cellulose, corn starch, starch), potato starch, sugar alcohols (mannitol, xylitol, sorbitol, erythritol, etc.), trehalose, inorganic salts, dextran, dextrin, β-cyclodextrin, sucrose fatty acid ester, soybean lecithin, tragacanth powder, gum arabic, pullulan, kaolin, anhydrous lactose, anhydrous calcium hydrogen phosphate, anhydrous calcium hydrogen phosphate granules, magnesium aluminum metasilicate, methylcellulose, calcium hydrogen phosphate hydrate, calcium hydrogen phosphate granules, sodium hydrogen phosphate hydrate, potassium dihydrogen phosphate, calcium dihydrogen phosphate hydrate, sodium dihydrogen phosphate, magnesium aluminum silicate, calcium silicate, magnesium silicate, light anhydrous silicic acid, low-substituted hydroxypropyl cellulose, sodium starch glycolate, powdered reduced maltose syrup, carboxymethyl cellulose, carboxymethyl cellulose calcium, sodium carboxymethyl cellulose, etc. These can be used alone or in any combination of two or more. When the mass of the composition is set to 100 mass %, the proportion of the excipient contained therein is not limited as long as it does not adversely affect the effect of tranexamic acid, and for example, the range of 0.1 mass % to 70 mass % can be exemplified. Preferably, it is 0.5 mass % to 50 mass %, and more preferably, it is 1 mass % to 40 mass %. From the viewpoint of maintaining the color tone of the composition as white, the excipient preferably comprises one or more components selected from mannitol, microcrystalline cellulose and corn starch.

[0051] The binder is not limited as long as the effect of tranexamic acid is not impaired, and examples thereof include gum arabic, gelatin, pregelatinized starch, alginic acid, sodium alginate, carboxyvinyl polymer, agar, pullulan, dextrin, shellac, sucrose, tragacanth gum, tragacanth gum powder, xanthan gum, pectin, sodium polyacrylate, guar gum, corn starch, hydroxyethyl cellulose, hydroxypropyl cellulose, low-substituted hydroxypropyl cellulose, copovidone, hypromellose (2208), hypromellose (2906), hypromellose (2910), hypromellose acetate succinate, hypromellose phthalate (200731), hypromellose phthalate (220824), povidone (K25), povidone (K30), povidone (K90), polyvinyl alcohol (completely saponified), polyvinyl alcohol (partially saponified), methylcellulose, and magnesium aluminum metasilicate. When the mass of the composition is set to 100 mass %, the ratio of the binder contained therein is not limited as long as it does not adversely affect the effect of tranexamic acid, and can be, for example, in the range of 0.1 mass % to 10 mass %, preferably in the range of 0.5 mass % to 8 mass %, and more preferably in the range of 1 mass % to 5 mass %.

[0052] As disintegrant, it is not limited to the effect of tranexamic acid, for example, corn starch, potato starch, partially pregelatinized starch, hydroxypropyl starch, sodium starch glycolate, sodium carboxymethyl starch, sodium carboxymethyl starch with low degree of substitution, calcium carboxymethyl cellulose, low degree of substitution hydroxypropyl cellulose, cross-linked sodium carboxymethyl cellulose, microcrystalline cellulose, powdered cellulose, crospovidone, sodium carboxymethyl cellulose, agar powder, sodium bicarbonate, carboxymethyl cellulose, etc. When the mass of the composition is set to 100% by mass, the proportion of the disintegrant contained therein is not limited as long as it does not have a negative impact on the effect of tranexamic acid, for example, the range of 0.1% to 30% by mass can be illustrated. It is preferably 0.5% to 20% by mass, and more preferably 1% to 15% by mass.

[0053] The lubricant is not limited as long as the effect of tranexamic acid is not impaired, and examples thereof include magnesium stearate, calcium stearate, stearic acid, talc, sucrose fatty acid esters, sodium stearyl fumarate, carnauba wax, glycerol fatty acid esters, calcium stearate, light anhydrous silicic acid, and magnesium aluminum metasilicate.

[0054] The flavoring agent is not limited, and examples thereof include organic acids such as citric acid, tartaric acid, and malic acid, sodium glutamate, sodium 5'-inosinate, sodium 5-guanylate, sodium aspartate, and caramel.

[0055] The sweetener is not limited, and examples thereof include high-sweetness sweeteners such as saccharin sodium, dipotassium glycyrrhizinate, aspartame, stevia, rakan sugar (Japanese: ラカンカ), thaumatin, acesulfame potassium, sucralose, sucrose, fructose, glucose, lactose hydrate, anhydrous lactose, maltose, sorbitol, maltitol, mannitol, xylitol, erythritol, glycerin, inositol, reduced maltose syrup, palatinose, mixed sugar (Japanese: カップリングシュガー), and honey.

[0056] The coating agent is not limited, and examples thereof include ethyl acrylate-methyl methacrylate copolymer dispersion, acetylglycerol fatty acid ester, aminoalkyl methacrylate copolymer E, gum arabic, gum arabic powder, ammonium alkyl methacrylate copolymer, ethyl cellulose, ethyl cellulose aqueous dispersion, octyldecyl triglyceride, carnauba wax, carboxymethyl cellulose calcium, carboxymethyl cellulose sodium, hydrous silicon dioxide, dried aluminum hydroxide gel, dried methacrylic acid copolymer LD, triethyl citrate, glycerin, glycerol fatty acid ester, magnesium silicate, light anhydrous silicic acid, hydroxypropyl cellulose containing light anhydrous silicic acid, synthetic aluminum silicate, synthetic hydrotalcite, titanium oxide, Magnesium oxide, dimethylaminoethyl methacrylate / methyl methacrylate copolymer, sucrose fatty acid ester, aluminum hydroxide gel, stearyl alcohol, stearic acid, aluminum stearate, calcium stearate, polyethylene glycol stearate 40, magnesium stearate, purified gelatin, purified shellac, purified white sugar, gelatin, shellac, D-sorbitol, D-sorbitol liquid, talc, calcium carbonate, magnesium carbonate, precipitated calcium carbonate, low-substituted hydroxypropyl cellulose, concentrated glycerin, white shellac, white sugar, paraffin, hydroxypropyl cellulose, hydroxypropyl methylcellulose 2910 / titanium oxide / polyethylene glycol mixture, hypromellose (2208), hypromellose (2906), hypromellose (2910 ), Hydroxypropyl methylcellulose acetate succinate, Hydroxypropyl methylcellulose phthalate (200731), Hydroxypropyl methylcellulose phthalate (220824), Fumaric acid, stearic acid, polyvinyl alcohol acetal diethylamino acetate, hydroxypropyl methylcellulose 2910 mixture, Pullulan, Polyoxyethylene hydrogenated castor oil 40, Polyoxyethylene hydrogenated castor oil 60, Polyoxyethylene (105) polyoxypropylene (5) glycol, Polyoxyethylene (160) polyoxypropylene (30) glycol, Polysorbate 80, Polyvinyl alcohol acetal diethylamino acetate, Polyvinyl alcohol (completely saponified), Polyvinyl alcohol (partially saponified), Macrogol 300, Polyethylene glycol Alcohol 400, polyethylene glycol 600, polyethylene glycol 1500, polyethylene glycol 1540, polyethylene glycol 4000, polyethylene glycol 6000, polyethylene glycol 6000EP, polyethylene glycol 20000, polyethylene glycol 35000, mannitol, anhydrous citric acid, anhydrous silicic acid hydrate, phthalic anhydride, anhydrous calcium hydrogen phosphate, methacrylic acid copolymer L, methacrylic acid copolymer LD, methacrylic acid copolymer S, magnesium aluminum metasilicate, methyl methacrylate·methacrylic acid·methyl methacrylate copolymer, aluminum monostearate, glyceryl monostearate, sorbitan monostearate, sorbitan monolaurate, calcium sulfate, fumaric acid and DL-malic acid, etc.

[0057] The composition has a solid shape. As such a composition, tablets, granules, pills and powders can be cited. The composition is preferably a tablet or granule, more preferably a tablet or granule obtained by a process of mixing in the presence of water such as wet granulation. It should be noted that the tablet can be composed of a single layer or a multilayer structure of more than two layers.

[0058] Examples of tablets include bare tablets, plain tablets, sugar-coated tablets, orally disintegrating tablets, film-coated tablets, or chewable tablets. Tablets may also be multilayer tablets formed by stacking powders or granules of different compositions into two or more layers and compressing them. Depending on the desired composition, the film may be given properties such as rapid solubility, slow solubility, gastric solubility, and enteric solubility.

[0059] Regarding the size of the tablet (bare tablet or plain tablet), for example, in the case of a tablet formed into a round shape (cylindrical shape), the diameter can be in the range of about 2 mm to about 15 mm. It is preferably in the range of about 3 mm to about 12 mm. In addition, the thickness is not limited, but can be in the range of about 3 mm to about 10 mm.

[0060] The composition can be a solid preparation for oral administration. Such solid preparations can be temporarily packaged and airtightly stored using bottle packaging, PTP packaging, bag packaging, rod packaging, and SP packaging. In addition, they can be pillow-packed or stored in boxes, etc. As the material used in the pillow packaging, there is no particular limitation, and for example, resin films such as polypropylene film, polyethylene terephthalate film, and polyethylene film can be used, and materials formed by attaching aluminum foil to these resin films. It should be noted that, when worrying about hygroscopicity, desiccant, etc. can be stored in bottle packaging and pillow packaging at the same time.

[0061] The solid preparation for internal use may be in the form of the above-mentioned tablets, granules, pills and powders that can be administered orally.

[0062] The composition of the present invention may be present as a pharmaceutical composition, a cosmetic composition, a food and beverage composition, etc., which is expected to be white as a final product. The composition preferably exhibits white color, but when the discoloration suppressing effect of tranexamic acid is insufficient, such as when the amount of tranexamic acid in the composition is small, the composition may exhibit yellowish white, pale yellowish white, pale yellow, yellowish white, or pale yellow.

[0063] From the whitening effect of niacinamide, ascorbic acid, and tranexamic acid, it is intended to provide the composition in the form of a cosmetic composition, preferably a cosmetic composition for internal use. When the composition is used for cosmetic purposes, it is preferably further comprised of calcium pantothenate and pyridoxine hydrochloride. The content of these compounds can be appropriately adjusted by a person skilled in the art, and therefore it is not intended to be limited. The amount of calcium pantothenate is 1 mg to 1200 mg, preferably 5 mg to 600 mg, and more preferably 10 mg to 100 mg, relative to the composition administered per day, and the amount of pyridoxine hydrochloride is 0.5 mg to 200 mg, preferably 1 mg to 100 mg, and more preferably 2 mg to 50 mg, relative to the composition administered per day.

[0064] When used in this specification, whitening includes the prevention and / or treatment of pigmentation disorders such as spots (including liver spots, age-related pigment spots, etc.), freckles, sun spots, dark skin, and melanosis caused by drugs such as steroids.

[0065] When provided in the form of a composition that exerts a whitening effect, the composition of the present invention may further include a known component that exhibits a whitening effect and a component that enhances the whitening effect. As these components, for example, L-cysteine ​​or its derivatives (N-acetyl-L-cysteine, L-homocysteine, L-cysteine, L-homocysteine, L-cysteine ​​sulfinic acid, S-sulfinyl-L-cysteine, S-sulfo-L-cysteine, cystine (a dimer of cysteine), etc.), pantothenic acid, its derivatives or their salts (pantothenic acid; pantothenate salts such as sodium pantothenate and calcium pantothenate; pantetheine, pantethine, phosphopantetheine, etc.), hydroquinone or its derivatives (hydroquinone; hydroquinone glycosides such as hydroquinone-β-D-glucose (arbutin), etc.), glucosamine or its derivatives (glucosamine; glucosamine esters such as acetylglucosamine; glucosamine methyl ether, etc.), hinokitiol or its derivatives (hinokitiol; hinokitiol glycosides such as hinokitiol glycosides, etc.), azelaic acid, its derivatives or their salts (zelaic acid; azelaic acid monoesters such as azelaic acid monoalkyl esters; azelaic acid diesters such as azelaic acid dialkyl esters, etc.), tocopherols (α-tocopherol, β-tocopherol, γ-tocopherol, δ-tocopherol, succinic acid d-α-tocopherol, etc.), ubiquinones (coenzyme Q6 (CoQ6), coenzyme Q7 (CoQ7), coenzyme Q8 (CoQ8), coenzyme Q9 (CoQ9), coenzyme Q10 (CoQ10)), carotenoids (carotene, lutein, violaxanthin, spirilaxanthin, globulin red pole hair bacillus, etc.), flavonoids (xanthophyll, lutein, violaxanthin, spirilaxanthin, globulin red pole hair bacillus, etc.), ketones, apigenin, luteolin and their glycosides, etc.), isoflavones or their derivatives (isoflavones; isoflavone glycosides, etc.), flavanones or their derivatives (naringenin, eriodictyol, naringin, etc.), catechins (catechin, catechin gallate, gallocatechin, etc.), flavonols (kaempferol, quercetin, myricetin and their glycosides, etc.), glycyrrhizic acid, its derivatives or their salts (glycyrrhizic acid; glycyrrhizic acid salts such as dipotassium glycyrrhizinate and monoammonium glycyrrhizinate, etc.), glycyrrhizic acid, its derivatives or their salts (glycyrrhizic acid; glycyrrhizic acid alkyl esters such as glycyrrhizic acid stearyl, etc.), kojic acid, its derivatives or their salts (kojic acid; kojic acid monobutyrate, kojic acid monodecanoate, kojic acid monopalmitate, kojic acid monostearate, etc. Kojic acid monoalkyl esters; kojic acid dialkyl esters such as kojic acid dibutyrate, kojic acid dipalmitate, kojic acid distearate, and kojic acid dioleate, etc.), ellagic acid, its derivatives or salts thereof (ellagic acid; ellagic acid ethers such as ellagic acid tetramethyl ether; ellagic acid acyl derivatives such as ellagic acid tetraacetate and ellagic acid tetrabenzoate, etc.), glutathione, its derivatives or salts thereof (glutathione; S-acyl glutathiones such as S-lactoyl glutathione; N,S-diacyl glutathione diesters such as N,S-dioctanoyl glutathione distearyl and N,S-dipalmitoyl glutathione dicetyl, etc.), resorcinol or its derivatives (resorcinol; 4-n-butylresorcinol, 4-isoamylresorcinol,4-cyclohexylresorcinol, 5-methylresorcinol and other alkylated resorcinols; 4-chlororesorcinol, 4-bromoresorcinol and other halogenated resorcinols, glycogen; coix seed, witch hazel (Hamamelis mamelodis), saxifrage (Saxifragastolonifera), agallocha, tea (Thea sinensis), polygonum cuspidatum, Melisa officinalis, thyme (Thymusvulgaris), Artemisia capillaris, Achillea milefolium, Hypericum erectum, Hypericumperforatum, Paeonia lactiflora, Paeonia suffruticosa, Glycyrrhiza glabra, Glycyrrhiza uralensis, Morus bombycis, Morusalba, Morus alba, Sophora flavescens, Artctostaphylos uva-ursl, Dictyopteris prolifera, Dictyota linearis, Sargassum fusiforme, Lomentaria catenata, Cassiope lycopodioides, Rhodymenia palmata, Sargassum ringgoldianum, Sargassum yezoense, Sargassum confusum, Sphaerotrichia divaricata, Droserarotundifolia, Drosera spatulata, Lavandula, Coptis japonicus, Coixlacryma-joli, Epigaea asiatica, Epigaearepens, pink passion fruit (Passifloraincarnata), egg fruit (Passiflora edulis), watermelon, Passiflora caerulea, Passifloraaltebilobata,Passiflora moluccana or Passiflora cochinchinensis, Passiflora cupiformis, Viola tricolor, Viola odorata, Violaceae, Viola japonica, Viola yedoensis, Viola verecunda, Viola diffusa, Viola patrinii, Viola acuminata, Nepalese violet, Viola patrini, Viola collina, Viola sororia, Viola grypoceras, Viola philippica, Viola vaginata, Viola verecunda, Clematis chinensis Osbeck, Clematis florida), Clematis patens, Clematis terniflora, Eucommia ulmoides; Euonymus trichocarpus Hayata, Euonymus oxyphyllus, Asparagus officinalis, Polygonum bistorta or Bistorta major, Pisum sativum, Rosa multiflora, Scutellaria baicalensis, Ononis, Rubus, Sophora flavescens, Millettia reticulata, Acanthopanax gracilistylus, Asiasarum sieboldii, Crataegus cuneata, Cassia nomame), white lily, Inula japonica, Morus alba, soybean, tea, Angelica acutiloba extract, molasses, Ampelopsis japonica Makino, beech, grape seed,Frode manita, humulus, rose (Rosa rugosa), papaya (Chaenomeles sinensis) or Pseudocydonia sinensis, Momordic agrosvenori, Aloe ferox, Althaea, Arnica, keiskei angelica, Artemisia capillaris, Urtica, Curcuma, Phellodendron amurense, Matricaria chamomilla, Lonicera japonica, Nasturtium officinale, Symphytum officinale, Salvia, Lithospermum erythrorhizon, Perilla, Betula platyphylla, Calendula officinalis, Sambucus sieboldiana, Typha latifolia), Sapindusmukurossi, Astragalus sinicus, Artemisia, Eucalyptus, Rosamultifiora, Ginkgo biloba, Alnus, Lyciumchinense, Micromelumminutum, Micromelum pubescens, Melothria indica, Mango, Melothria japonica, Rubus idaeus, Pyracantha fortuneana or their extracts; Placenta extract; etc., but not limited to the above substances. Among them, calcium pantothenate is preferred, and calcium pantothenate S type (trade name) can also be used as a granulated product of calcium pantothenate and calcium lactate. These ingredients can be combined with only one kind, and more than two kinds can also be combined. In the whitening composition (whitening agent), ingredients other than ingredients that show known whitening effects and ingredients that enhance whitening effects can also be further added. The amounts of these components added are not particularly limited as long as the effects of tranexamic acid are not impaired.

[0066] In a specific embodiment, 6 mg to 400 mg of nicotinamide, 10 mg to 3000 mg of ascorbic acid, and 50 mg to 3000 mg of tranexamic acid are added to the composition.

[0067] The above-mentioned dosage is an example of a daily dosage. When the composition is administered multiple times a day, the dosage may be divided into multiple times, for example, 2 to 4 times.

[0068] In a specific embodiment, the content of nicotinamide is 1% to 5% by mass, the content of ascorbic acid is 5% to 30% by mass, and the content of tranexamic acid is 20% to 60% by mass, based on the composition.

[0069] (Manufacturing method)

[0070] In a second embodiment, a method for producing a solid composition is provided, the method comprising contacting nicotinamide with ascorbic acid and tranexamic acid in the presence of water. The addition period of each component is not particularly limited. For example, tranexamic acid can be added before the start of discoloration, or can be added at an appropriate period after the start of discoloration. From the viewpoint of maintaining the color of the composition as white, with respect to water, it is preferably added after tranexamic acid is coordinated with the combination of nicotinamide and ascorbic acid and fully mixed.

[0071] The amount of tranexamic acid is appropriately adjusted according to the amounts of nicotinamide and ascorbic acid. For example, when nicotinamide is about 10 mg to about 70 mg, about 15 mg to about 65 mg, about 20 mg to about 60 mg, about 25 mg to about 55 mg, about 30 mg to about 50 mg, or about 35 mg to about 45 mg, and ascorbic acid is about 50 mg to about 2000 mg, about 75 mg to about 1750 mg, about 100 mg to about 1500 mg, about 200 mg to about 1000 mg, or about 250 mg to about 350 mg, the amount of tranexamic acid is appropriately adjusted within the range of 500 mg to about 1000 mg, about 550 mg to about 950 mg, about 600 mg to about 900 mg, about 650 mg to about 850 mg, or about 700 mg to about 800 mg.

[0072] The above-mentioned compounding amount is an example, and the added amount of tranexamic acid can be increased or decreased depending on the degree of the desired discoloration suppressing effect.

[0073] Appropriate formulation additives may be added to the composition. As formulation additives, excipients, binders, disintegrants, disintegration aids, lubricants, stabilizers, surfactants, antioxidants, buffers, pH adjusters, dispersants, cosolvents, flow agents, glossing agents, flavoring agents, sweeteners, cooling agents, colorants, deodorants, fragrances, adsorbents, sugar coatings, coating agents, suspending agents, antistatic agents, plasticizers and aromatics can be appropriately selected within the range that does not impair the effect of tranexamic acid, and an appropriate amount can be added.

[0074] The composition can be produced by a conventional method for producing a solid preparation. Such a production method includes granulation granules, and examples thereof include wet granulation methods represented by high-speed stirring granulation methods and fluidized bed granulation methods.

[0075] Since ascorbic acid is a component with high adhesion, when the amount of ascorbic acid in the composition is large, in order to avoid tableting obstacles during tableting, it is preferred to use granulated particles to reduce the surface area. Thus, the particles containing the drug are fully covered with the lubricant, and the contact between the drug and the mortar and pestle during tableting can be reduced.

[0076] In a specific embodiment, the manufacturing method may include a process of wet granulating nicotinamide, ascorbic acid and tranexamic acid using water or an aqueous solution or dispersion of a binder, and other processes optionally commonly used in the art for manufacturing solid compositions. As wet granulation, commonly used mixing and stirring granulation, high-speed stirring granulation, fluidized bed granulation or rolling granulation can be used, preferably high-speed stirring granulation or fluidized bed granulation, more preferably fluidized bed granulation. In order to manufacture the desired granulated product and its molded product, any process such as drying process and granulation can be implemented after granulation.

[0077] The granules obtained by wet granulation may be mixed and compression-molded to form the composition in the form of tablets. In addition, the granules and tablets may be coated with sugar or film by a known method.

[0078] The coating (coating) using sugar coating or film can be implemented by, for example, pan coating, fluidized bed coating, rolling coating, dry coating, or a combination of these methods. In this case, the sugar coating component or film component can be dissolved or dispersed in water or an organic solvent (ethanol, etc.) according to a conventional method and spray-coated. Alternatively, the film component can be directly sprayed and dry-coated by applying heat or pressure.

[0079] The sugar coating ingredients used to form the sugar coating are not limited, and examples thereof include monosaccharides and disaccharides such as sucrose (white sugar, refined white sugar), fructose, glucose, lactose hydrate, anhydrous lactose, and trehalose; sugars such as erythritol, mannitol, sorbitol, xylitol, maltitol, powdered reduced maltose syrup, and reduced lactose. In addition, the sugar coating liquid may further include gum arabic, gum arabic powder, ethyl cellulose, carnauba wax, sodium carboxymethyl cellulose, stearic acid, polyethylene glycol stearate 40, refined gelatin, refined shellac, gelatin, shellac, talc, precipitated calcium carbonate, white shellac, hydroxypropyl cellulose, hypromellose (2208), hypromellose (2906), hypromellose (2910), pullulan, povidone (K25), povidone (K30 ), povidone (K90), polyoxyethylene (105) polyoxypropylene (5) glycol, polyvinyl alcohol (partially saponified), polyethylene glycol 1500, polyethylene glycol 4000, polyethylene glycol 6000, mannitol, monocalcium dihydrogen phosphate, calcium dihydrogen phosphate, calcium sulfate, calcium lactate, kaolin, titanium oxide, ferric oxide, yellow ferric oxide, black copper iron oxide, sodium chlorophyll, copper chlorophyll, riboflavin, riboflavin butyrate, riboflavin sodium phosphate, etc.

[0080] Examples of the film coating agent include water-soluble polymers, gastric-soluble polymers, and enteric polymers. Examples of the water-soluble polymers include, but are not limited to, methylcellulose, hydroxypropylmethylcellulose (2208), hydroxypropylmethylcellulose (2906), hydroxypropylmethylcellulose (2910), hydroxypropylcellulose, polyethylene glycol, polyvinyl alcohol (completely saponified), polyvinyl alcohol (partially saponified), polyvinyl alcohol·acrylic acid·methyl methacrylate copolymer, polyvinyl pyrrolidone, polyethylene glycol 300, polyethylene glycol 400, polyethylene glycol 600, polyethylene glycol 1500, polyethylene glycol 1540, polyethylene glycol 4000, polyethylene glycol 6000, polyvinyl alcohol·polyethylene glycol·graft copolymer, and the like. As gastric soluble polymer compounds, there are no restrictions, for example, polyvinyl acetal polymers such as polyvinyl acetal diethylaminoacetate, gastric soluble methacrylic acid polymers such as methyl methacrylate-butyl methacrylate-dimethylaminoethyl methacrylate copolymers, methyl methacrylate-diethylaminoethyl methacrylate copolymers, etc. As enteric polymer compounds, there are no restrictions, for example, enteric methacrylic acid-ethyl acrylate copolymers, methacrylic acid-methyl methacrylate copolymers, methacrylic acid copolymer S, methyl acrylate-methyl methacrylate-methacrylic acid copolymers, etc.; enteric soluble cellulose polymers such as cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, polyvinyl acetate phthalate, carboxymethyl ethyl cellulose, etc. In addition, the coating solution may also contain talc, titanium oxide, gum arabic, gum arabic powder, ethyl cellulose, carnauba wax, sodium carboxymethyl cellulose, stearic acid, polyethylene glycol stearate 40, refined gelatin, refined shellac, gelatin, shellac, talc, precipitated calcium carbonate, white shellac, pullulan, povidone (K25), povidone (K30), povidone (K90), polyoxyethylene (105) polyoxypropylene (5) glycol, polyethylene glycol 1500, polyethylene glycol 4000, polyethylene glycol 6000, mannitol, monocalcium dihydrogen phosphate, calcium dihydrogen phosphate, calcium sulfate, calcium lactate, kaolin, titanium oxide, ferric oxide, yellow ferric oxide, black copper iron oxide (Japanese: black copper iron oxide), sodium chlorophyll, copper chlorophyll, riboflavin, riboflavin butyrate, riboflavin sodium phosphate, etc.

[0081] The produced composition preferably exhibits white color, but may exhibit yellowish white, pale yellowish white, pale yellow, yellowish white or pale yellow when the discoloration suppressing effect of tranexamic acid is insufficient, such as when the amount of tranexamic acid in the composition is small.

[0082] (Discoloration suppression method)

[0083] In a third aspect, there is provided a method for inhibiting discoloration of a solid composition, the method comprising the step of contacting nicotinamide, ascorbic acid, and tranexamic acid in the presence of water.

[0084] The color of the combination of nicotinamide and ascorbic acid can change from white to slightly yellowish white, pale yellowish white, slightly yellow, yellowish white, pale yellow, and yellow, and tranexamic acid can be used as an active ingredient to prevent such yellowing. The amount of tranexamic acid as an active ingredient of the discoloration inhibitor is appropriately adjusted according to the amounts of nicotinamide and ascorbic acid. For example, when the amount of nicotinamide is about 10 mg to about 70 mg, about 15 mg to about 65 mg, about 20 mg to about 60 mg, about 25 mg to about 55 mg, about 30 mg to about 50 mg, or about 35 mg to about 45 mg, and when the amount of ascorbic acid is about 50 mg to about 2000 mg, about 75 mg to about 1750 mg, about 100 mg to about 1500 mg, about 200 mg to about 1000 mg, or about 250 mg to about 350 mg, the amount of tranexamic acid is appropriately adjusted within the range of 500 mg to about 1000 mg, about 550 mg to about 950 mg, about 600 mg to about 900 mg, about 650 mg to about 850 mg, or about 700 mg to about 800 mg.

[0085] The above-mentioned blending amounts are merely examples, and the amount of tranexamic acid added may be increased or decreased depending on the desired discoloration suppressing effect.

[0086] The addition period of each component is not particularly limited. For example, tranexamic acid can be added before the color change starts, or it can be added at an appropriate period after the color change starts. From the viewpoint of maintaining the color of the composition as white, with regard to water, it is preferably added after tranexamic acid is coordinated with the combination of nicotinamide and ascorbic acid and fully mixed.

[0087] The discoloration inhibition effect is confirmed in a mixture immediately after mixing the three components of nicotinamide, ascorbic acid and tranexamic acid, a granulated product obtained thereafter, and a molded product thereof. The discoloration inhibition method may further include any steps. For example, from the viewpoint of maintaining the discoloration inhibition effect, it is preferred that the granulated product, etc., be stored at a temperature below room temperature in an airtight container in which moisture permeability is suppressed. Here, "airtight container" is defined in the 18th revision of the Japanese Pharmacopoeia as a container in which solid or liquid foreign matter will not invade during transportation or storage, and in which the loss, wind decomposition, deliquescence or evaporation of the content of the drug can be prevented. As such an airtight container, a common tablet bottle can be cited.

[0088] Hereinafter, the present invention will be described in more detail with reference to Examples and Comparative Examples, but the present invention is not limited to these Examples and Comparative Examples.

[0089] Example

[0090] (Comparative Example 1)

[0091] Nicotinamide (manufactured by DSM) and ascorbic acid (manufactured by DSM) were mixed in an agate mortar at the ratio of the blending amount shown in Table 1 (operation 1), and 3% by mass of purified water was added dropwise to the total mass of the mixture to form granules (operation 2), followed by drying in a constant temperature chamber at 60° C. for 1 hour to obtain granules (operation 3). The color tone of the sample was observed at each time point of operation 1, operation 2, and operation 3.

[0092] (Comparative Example 2)

[0093] Nicotinamide (manufactured by DSM), ascorbic acid (manufactured by DSM) and mannitol (D-mannitol: manufactured by B Food Science) were mixed in an agate mortar at the ratio of the blending amount shown in Table 1 (operation 1), and 3% by mass of purified water was added dropwise to the total mass of the mixture to form granules (operation 2), and then dried in a constant temperature chamber at 60° C. for 1 hour to obtain granules (operation 3). The color tone of the sample was observed at each time point of operation 1, operation 2, and operation 3.

[0094] (Comparative Example 3)

[0095] Nicotinamide (manufactured by DSM), ascorbic acid (manufactured by DSM) and corn starch (manufactured by Matsutani Chemical Industry Co., Ltd.) were mixed in an agate mortar at the ratio of the blending amount shown in Table 1 (operation 1), and granulation was performed by dropping 7% by mass of purified water relative to the total mass of the mixture (operation 2), and then dried in a constant temperature chamber at 60° C. for 1 hour to obtain granules (operation 3). The color tone of the sample was observed at each time point of operation 1, operation 2, and operation 3.

[0096] (Comparative Example 4)

[0097] Nicotinamide (manufactured by DSM), ascorbic acid (manufactured by DSM) and microcrystalline cellulose (Ceolus PH-101: manufactured by Asahi Kasei Corporation) were mixed in an agate mortar at the ratio of the blending amount shown in Table 1 (operation 1), and granulation was performed by dropping 12% by mass of purified water relative to the total mass of the mixture (operation 2), and then dried in a constant temperature chamber at 60° C. for 1 hour to obtain granules (operation 3). The color tone of the sample was observed at each time point of operation 1, operation 2, and operation 3.

[0098] (Example 1)

[0099] Nicotinamide (manufactured by DSM), ascorbic acid (manufactured by DSM) and tranexamic acid (manufactured by Hunan Dongting Pharmaceutical Co., Ltd.) were mixed in an agate mortar at the ratio of the blending amount shown in Table 1 (operation 1), and 3% by mass of purified water was added dropwise to the total mass of the mixture to form granules (operation 2), and then dried in a constant temperature chamber at 60° C. for 1 hour to obtain granules (operation 3). The color tone of the sample was observed at each time point of operation 1, operation 2, and operation 3.

[0100] (Example 2)

[0101] Nicotinamide (manufactured by DSM), ascorbic acid (manufactured by DSM), tranexamic acid (manufactured by Hunan Dongting Pharmaceutical Co., Ltd.) and calcium pantothenate (calcium pantothenate S type: manufactured by BASF Japan Co., Ltd.) were mixed in an agate mortar at the ratio of the blending amount shown in Table 1 (operation 1), and granulation was performed by dropping 3% by mass of purified water relative to the total mass of the mixture (operation 2), and then drying was performed in a constant temperature chamber at 60° C. for 1 hour to obtain granules (operation 3). The color tone of the sample was observed at each time point of operation 1, operation 2, and operation 3.

[0102] (Example 3)

[0103] Nicotinamide (manufactured by DSM), ascorbic acid (manufactured by DSM), tranexamic acid (manufactured by Hunan Dongting Pharmaceutical Co., Ltd.), and pyridoxine hydrochloride (manufactured by DSM) were mixed in an agate mortar at the ratio of the blending amount shown in Table 1 (operation 1), and 3% by mass of purified water was added dropwise to the total mass of the mixture to form granules (operation 2), and then dried in a constant temperature chamber at 60° C. for 1 hour to obtain granules (operation 3). The color tone of the sample was observed at each time point of operation 1, operation 2, and operation 3.

[0104] (Example 4)

[0105] Nicotinamide (manufactured by DSM), ascorbic acid (manufactured by DSM), tranexamic acid (manufactured by Hunan Dongting Pharmaceutical Co., Ltd.), calcium pantothenate (calcium pantothenate S type: manufactured by BASF Japan Co., Ltd.), and pyridoxine hydrochloride (manufactured by DSM) were mixed in an agate mortar at the ratio of the blending amount shown in Table 1 (operation 1), and granulation was performed by dropping 3% by mass of purified water relative to the total mass of the mixture (operation 2), and then drying was performed in a constant temperature chamber at 60° C. for 1 hour to obtain granules (operation 3). The color tone of the sample was observed at each time point of operation 1, operation 2, and operation 3.

[0106] (Example 5)

[0107] Nicotinamide (manufactured by DSM), ascorbic acid (manufactured by DSM), tranexamic acid (manufactured by Hunan Dongting Pharmaceutical Co., Ltd.) and mannitol (D-mannitol: manufactured by B Food Science Co., Ltd.) were mixed in an agate mortar at the ratio of the blending amount shown in Table 1 (operation 1), and 3% by mass of purified water was added dropwise to the total mass of the mixture to granulate (operation 2), and then dried in a constant temperature chamber at 60° C. for 1 hour to obtain granules (operation 3). The color tone of the sample was observed at each time point of operation 1, operation 2, and operation 3.

[0108] (Example 6)

[0109] Nicotinamide (manufactured by DSM), ascorbic acid (manufactured by DSM), tranexamic acid (manufactured by Hunan Dongting Pharmaceutical Co., Ltd.) and corn starch (manufactured by Matsutani Chemical Industry Co., Ltd.) were mixed in an agate mortar at the ratio of the blending amount shown in Table 1 (operation 1), and 5% by mass of purified water was added dropwise to the total mass of the mixture to granulate (operation 2), and then dried in a constant temperature chamber at 60° C. for 1 hour to obtain granules (operation 3). The color tone of the sample was observed at each time point of operation 1, operation 2, and operation 3.

[0110] (Example 7)

[0111] Nicotinamide (manufactured by DSM), ascorbic acid (manufactured by DSM), tranexamic acid (manufactured by Hunan Dongting Pharmaceutical Co., Ltd.), and microcrystalline cellulose (Ceolus PH-101: manufactured by Asahi Kasei Corporation) were mixed in an agate mortar at the ratio of the blending amount shown in Table 1 (operation 1), and 5% by mass of purified water was added dropwise to the total mass of the mixture to form granules (operation 2), and then dried in a constant temperature chamber at 60° C. for 1 hour to obtain granules (operation 3). The color tone of the sample was observed at each time point of operation 1, operation 2, and operation 3.

[0112] Regarding the evaluation of the color tone change, the degree of change in the color tone of the sample at the operation 3 moment compared with the color tone of the sample at the operation 1 moment was evaluated in the following 5 levels, namely, -: no change, ±: very small change (white to slightly yellowish white), +: slight change (white to slightly yellowish white or slightly yellow), ++: clear change (white to yellowish white or slightly yellow), +++: significant change (white to yellow). The evaluation results of each example are shown in Table 1.

[0113] [Table 1]

[0114]

[0115] The formulation examples of a solid composition containing nicotinamide, ascorbic acid and tranexamic acid and a solid composition containing nicotinamide and ascorbic acid as a reference example are shown in the table below.

[0116] [Table 2]

[0117]

[0118] [Table 3]

[0119]

Claims

1. A solid composition comprising nicotinamide, ascorbic acid and tranexamic acid.

2. The solid composition according to claim 1, further comprising calcium pantothenate.

3. The solid composition according to claim 1 or 2, further comprising pyridoxine hydrochloride.

4. The solid composition according to any one of claims 1 to 3, wherein The composition administered per day contains 6 mg to 400 mg of nicotinamide, 10 mg to 3000 mg of ascorbic acid, and 50 mg to 3000 mg of tranexamic acid.

5. The solid composition according to any one of claims 1 to 3, wherein The content of nicotinamide is 1% to 5% by mass, the content of ascorbic acid is 5% to 30% by mass, and the content of tranexamic acid is 20% to 60% by mass based on the composition. 6 . The solid composition according to claim 1 , which is in the form of a tablet.

7. The solid composition according to any one of claims 1 to 6, wherein Tablets are in the form of bare tablets, plain tablets, sugar-coated tablets, orally disintegrating tablets, film-coated tablets or chewable tablets. 8 . The solid composition according to claim 1 , further comprising one or more components selected from the group consisting of microcrystalline cellulose, mannitol and corn starch.

9. The solid composition according to any one of claims 1 to 8, wherein The combination of niacinamide, ascorbic acid, and tranexamic acid appears white.

Citation Information

Cited By

  • Tranexamic acid oral dissolving system for improving bioavailability

    CN119656136A